The Expression Level of Neutrophil CD64 Is a Useful Marker of Systemic Inflammation Associated with HIV Infection

Fujiko Mitsumoto-Kaseida, Murata Masayuki, Kazuya Ura, Koji Takayama, Satoshi Hiramine, Motohiro Shimizu, Kazuhiro Toyoda, Eiichi Ogawa, Norihiro Furusyo

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

CD64 is an Fc-gamma-receptor type 1. The expression level of neutrophil CD64 (nCD64) is a known bacterial infection marker, and it also increases in viral infections. We examined the absolute nCD64 before and after the initiation of antiretroviral therapy (ART) to determine its role as an infection and inflammation marker of human immunodeficiency virus (HIV) infection. In this prospective observational study, 94 HIV-infected patients were enrolled and classified into ART (n = 62), ART naive (n = 24), and acute/early phase groups (n = 8). The median nCD64 was 1,430 molecules/cell in the ART group, 2,994 in the ART naive group, 4,625 in the acute/early phase group, and 1,196 in the healthy control group. The nCD64 in the ART group was significantly higher compared with the healthy controls (p = .041), and the nCD64 in the ART naive and acute/early phase groups was significantly higher compared with the ART group (both p < .001). In the ART naive group, nCD64 was significantly higher in patients with than without concomitant infections (3,942 ± 1,519 vs. 2,300 ± 784, p = .004). However, this was influenced by the fact that nCD64 elevated as the stage of HIV infection progressed. nCD64 decreased significantly during the 24 weeks after starting ART (p = .004), although an upward trend in nCD64 was observed at weeks 2 and 4, without symptoms. When immune reconstitution inflammatory syndrome occurred, nCD64 elevated with a wider range than did C-reactive protein. This preliminary study suggests that nCD64 would be useful as a marker of the systemic inflammation of HIV-infected patients.

元の言語英語
ページ(範囲)147-156
ページ数10
ジャーナルAIDS Research and Human Retroviruses
33
発行部数2
DOI
出版物ステータス出版済み - 2 1 2017

Fingerprint

Virus Diseases
Neutrophils
HIV
Inflammation
Group Psychotherapy
Immune Reconstitution Inflammatory Syndrome
Therapeutics
IgG Receptors
Infection
Bacterial Infections
C-Reactive Protein
Observational Studies
Prospective Studies
Control Groups

All Science Journal Classification (ASJC) codes

  • Immunology
  • Virology
  • Infectious Diseases

これを引用

The Expression Level of Neutrophil CD64 Is a Useful Marker of Systemic Inflammation Associated with HIV Infection. / Mitsumoto-Kaseida, Fujiko; Masayuki, Murata; Ura, Kazuya; Takayama, Koji; Hiramine, Satoshi; Shimizu, Motohiro; Toyoda, Kazuhiro; Ogawa, Eiichi; Furusyo, Norihiro.

:: AIDS Research and Human Retroviruses, 巻 33, 番号 2, 01.02.2017, p. 147-156.

研究成果: ジャーナルへの寄稿記事

Mitsumoto-Kaseida, Fujiko ; Masayuki, Murata ; Ura, Kazuya ; Takayama, Koji ; Hiramine, Satoshi ; Shimizu, Motohiro ; Toyoda, Kazuhiro ; Ogawa, Eiichi ; Furusyo, Norihiro. / The Expression Level of Neutrophil CD64 Is a Useful Marker of Systemic Inflammation Associated with HIV Infection. :: AIDS Research and Human Retroviruses. 2017 ; 巻 33, 番号 2. pp. 147-156.
@article{0d865651656749d18c587f94ea05d1c1,
title = "The Expression Level of Neutrophil CD64 Is a Useful Marker of Systemic Inflammation Associated with HIV Infection",
abstract = "CD64 is an Fc-gamma-receptor type 1. The expression level of neutrophil CD64 (nCD64) is a known bacterial infection marker, and it also increases in viral infections. We examined the absolute nCD64 before and after the initiation of antiretroviral therapy (ART) to determine its role as an infection and inflammation marker of human immunodeficiency virus (HIV) infection. In this prospective observational study, 94 HIV-infected patients were enrolled and classified into ART (n = 62), ART naive (n = 24), and acute/early phase groups (n = 8). The median nCD64 was 1,430 molecules/cell in the ART group, 2,994 in the ART naive group, 4,625 in the acute/early phase group, and 1,196 in the healthy control group. The nCD64 in the ART group was significantly higher compared with the healthy controls (p = .041), and the nCD64 in the ART naive and acute/early phase groups was significantly higher compared with the ART group (both p < .001). In the ART naive group, nCD64 was significantly higher in patients with than without concomitant infections (3,942 ± 1,519 vs. 2,300 ± 784, p = .004). However, this was influenced by the fact that nCD64 elevated as the stage of HIV infection progressed. nCD64 decreased significantly during the 24 weeks after starting ART (p = .004), although an upward trend in nCD64 was observed at weeks 2 and 4, without symptoms. When immune reconstitution inflammatory syndrome occurred, nCD64 elevated with a wider range than did C-reactive protein. This preliminary study suggests that nCD64 would be useful as a marker of the systemic inflammation of HIV-infected patients.",
author = "Fujiko Mitsumoto-Kaseida and Murata Masayuki and Kazuya Ura and Koji Takayama and Satoshi Hiramine and Motohiro Shimizu and Kazuhiro Toyoda and Eiichi Ogawa and Norihiro Furusyo",
year = "2017",
month = "2",
day = "1",
doi = "10.1089/aid.2016.0107",
language = "English",
volume = "33",
pages = "147--156",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - The Expression Level of Neutrophil CD64 Is a Useful Marker of Systemic Inflammation Associated with HIV Infection

AU - Mitsumoto-Kaseida, Fujiko

AU - Masayuki, Murata

AU - Ura, Kazuya

AU - Takayama, Koji

AU - Hiramine, Satoshi

AU - Shimizu, Motohiro

AU - Toyoda, Kazuhiro

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

PY - 2017/2/1

Y1 - 2017/2/1

N2 - CD64 is an Fc-gamma-receptor type 1. The expression level of neutrophil CD64 (nCD64) is a known bacterial infection marker, and it also increases in viral infections. We examined the absolute nCD64 before and after the initiation of antiretroviral therapy (ART) to determine its role as an infection and inflammation marker of human immunodeficiency virus (HIV) infection. In this prospective observational study, 94 HIV-infected patients were enrolled and classified into ART (n = 62), ART naive (n = 24), and acute/early phase groups (n = 8). The median nCD64 was 1,430 molecules/cell in the ART group, 2,994 in the ART naive group, 4,625 in the acute/early phase group, and 1,196 in the healthy control group. The nCD64 in the ART group was significantly higher compared with the healthy controls (p = .041), and the nCD64 in the ART naive and acute/early phase groups was significantly higher compared with the ART group (both p < .001). In the ART naive group, nCD64 was significantly higher in patients with than without concomitant infections (3,942 ± 1,519 vs. 2,300 ± 784, p = .004). However, this was influenced by the fact that nCD64 elevated as the stage of HIV infection progressed. nCD64 decreased significantly during the 24 weeks after starting ART (p = .004), although an upward trend in nCD64 was observed at weeks 2 and 4, without symptoms. When immune reconstitution inflammatory syndrome occurred, nCD64 elevated with a wider range than did C-reactive protein. This preliminary study suggests that nCD64 would be useful as a marker of the systemic inflammation of HIV-infected patients.

AB - CD64 is an Fc-gamma-receptor type 1. The expression level of neutrophil CD64 (nCD64) is a known bacterial infection marker, and it also increases in viral infections. We examined the absolute nCD64 before and after the initiation of antiretroviral therapy (ART) to determine its role as an infection and inflammation marker of human immunodeficiency virus (HIV) infection. In this prospective observational study, 94 HIV-infected patients were enrolled and classified into ART (n = 62), ART naive (n = 24), and acute/early phase groups (n = 8). The median nCD64 was 1,430 molecules/cell in the ART group, 2,994 in the ART naive group, 4,625 in the acute/early phase group, and 1,196 in the healthy control group. The nCD64 in the ART group was significantly higher compared with the healthy controls (p = .041), and the nCD64 in the ART naive and acute/early phase groups was significantly higher compared with the ART group (both p < .001). In the ART naive group, nCD64 was significantly higher in patients with than without concomitant infections (3,942 ± 1,519 vs. 2,300 ± 784, p = .004). However, this was influenced by the fact that nCD64 elevated as the stage of HIV infection progressed. nCD64 decreased significantly during the 24 weeks after starting ART (p = .004), although an upward trend in nCD64 was observed at weeks 2 and 4, without symptoms. When immune reconstitution inflammatory syndrome occurred, nCD64 elevated with a wider range than did C-reactive protein. This preliminary study suggests that nCD64 would be useful as a marker of the systemic inflammation of HIV-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=85012079644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012079644&partnerID=8YFLogxK

U2 - 10.1089/aid.2016.0107

DO - 10.1089/aid.2016.0107

M3 - Article

VL - 33

SP - 147

EP - 156

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 2

ER -